
-
Stock markets brush aside higher US tariffs
-
Siemens warns US tariffs causing investment caution
-
Influx of Afghan returnees fuels Kabul housing crisis
-
Israeli security cabinet to hold talks over future Gaza war plans
-
Macron urges tougher line in standoff with Algeria
-
UK says first migrants held under return deal with France
-
Ukraine's funeral workers bearing the burden of war
-
India exporters say 50% Trump levy a 'severe setback'
-
Germany factory output lowest since pandemic in 2020
-
Thailand and Cambodia agree to extend peace pact
-
Third-hottest July on record wreaks climate havoc
-
Trump-Putin meeting agreed for 'coming days', venue set: Kremlin
-
Frankfurt sign Japan winger Doan until 2030
-
Swiss reel from 'horror scenario' after US tariff blow
-
Apple to hike investment in US to $600 bn over four years
-
Asian markets rise as traders look past Trump chip threat
-
Higher US tariffs kick in for dozens of trading partners
-
Deliveroo slips back into loss on DoorDash takeover costs
-
'Dog ate my passport': All Black rookie in Argentina trip pickle
-
US tariffs prompt Toyota profit warning
-
Eddie Palmieri, Latin music trailblazer, dies at 88
-
Japan's World Cosplay Summit to escape summer heat in 2027
-
China exports top forecasts as EU, ASEAN shipments offset US drop
-
Cockatoos can bust a move: Australian research
-
Arrest warrant sought for South Korea's ex-first lady Kim
-
Khachanov topples Zverev to book ATP Toronto title clash with Shelton
-
Wallabies' White out of short-lived retirement for South Africa Tests
-
China says trade jumped in July, beating forecasts
-
Struggling Test opener Konstas sent on Australia A tour of India
-
Mo'unga to return to New Zealand in time for World Cup build-up
-
Higher US tariffs take effect on dozens of economies
-
Sony hikes profit forecasts after strong quarter for games
-
Osaka books WTA Montreal title clash with Canadian teen Mboko
-
Pacific microstate sells first passports to fund climate action
-
Kinky knots: Japanese bondage becomes art
-
Markets rise as Trump chip exemptions boost tech giants
-
Japanese population sees record drop in 2024
-
United Airlines flights grounded in the US
-
Khachanov topples Zverev to reach ATP Toronto final
-
Mexican authorities accuse Adidas of cultural appropriation
-
World Cup host Morocco under pressure to save stray dogs
-
Trump's 'dividend' promise for Americans leaves open questions
-
Dangerous dreams: Inside internet's 'sleepmaxxing' craze
-
For Argentine farmers, Milei's free-market reforms fall short
-
Bank of England set to cut rate as UK economy weakens
-
Canadian teen Mboko beats Rybakina to reach WTA Montreal final
-
Ohtani homers for 1,000th MLB hit in Dodgers defeat
-
Trump hikes India levy over Russian oil as tariff deadline looms
-
Arrive AI to Hold Inaugural Quarterly Results Call
-
Salomon Brothers: Addressing Crypto's Wallet Problem
RYCEF | 1.17% | 14.5 | $ | |
CMSC | -0.52% | 22.95 | $ | |
NGG | 0.03% | 72.3 | $ | |
RBGPF | 1.42% | 76 | $ | |
VOD | 1.77% | 11.3 | $ | |
GSK | -1.55% | 36.75 | $ | |
CMSD | 0.13% | 23.54 | $ | |
SCU | 0% | 12.72 | $ | |
RIO | 0.65% | 60.09 | $ | |
SCS | 0.19% | 15.99 | $ | |
BTI | 0.99% | 56.4 | $ | |
RELX | -3.65% | 48.81 | $ | |
AZN | -1.2% | 73.6 | $ | |
BCC | -4.64% | 82.92 | $ | |
JRI | 0.6% | 13.34 | $ | |
BCE | -1.33% | 23.25 | $ | |
BP | 0.83% | 33.88 | $ |

Massachusetts Cannabis Contamination Crisis Exposes Federal Negligence While DEA Targets Science, Not Safety
Where Is the DEA? The Real Threat Isn't Research-It's Rotten Weed.
"This is the height of hypocrisy," said Duane Boise, CEO MMJ. "DEA bureaucrats are blocking clean cannabis grown in a DEA inspected cultivation facility, while contaminated products circulate freely under their watch. The agency has abandoned its duty to protect patients."
WASHINGTON, DC / ACCESS Newswire / August 7, 2025 / While the Massachusetts Cannabis Control Commission scrambles to contain a major public health scandal involving 544 contaminated marijuana samples, Thomas Prevoznik and the Drug Enforcement Administration (DEA)-the agency that claims to "protect public health and safety from the dangers of drugs"-is nowhere to be found.

According to a Public Health and Safety Advisory issued today by the Massachusetts Commission, contaminated and potentially contaminated marijuana products were sold throughout the state between April 1, 2024, and April 15, 2025. The issue? The products failed Total Yeast and Mold testing -a serious risk to patients and consumers, especially those who are immunocompromised. Yet this failure of regulatory oversight occurred right under DEA's nose, in a federally illegal marketplace they claim to police.
So, we ask again: Where is the DEA?
Moldy Marijuana, Real Harm
Massachusetts authorities have confirmed that hundreds of samples tested positive for contaminants but were somehow allowed to enter commercial circulation. This isn't about labeling violations or clerical errors-it's about inhaled mold, a known trigger for respiratory infections, allergic reactions, and even long-term lung damage.
The contaminated products were tracked using Metrc, a seed-to-sale traceability system required by law. The system worked. But what failed? Federal oversight, accountability, and DEA enforcement.
DEA Targets Science, Not Safety
While moldy weed was being sold to unsuspecting patients, what was the DEA doing?
Blocking MMJ BioPharma Cultivation from producing pharmaceutical grade cannabis for FDA approved clinical trials.
Sabotaging medical marijuana research with unconstitutional Administrative Law Judge (ALJ) proceedings.
Wasting time litigating against compliant, registered entities seeking to cure Huntington's Disease and Multiple Sclerosis.
Upholding a hypocritical regime where unregulated street level weed flourishes, while federally compliant applicants like MMJ BioPharma Cultrivation are stonewalled for trying to protect patients and follow science.
Let's be clear: the DEA is not protecting public health. It's obstructing it.
The Real Threat Isn't Research-It's Rotten Weed
The DEA's warped priorities are now a matter of public danger. Instead of helping to build a controlled, pharmaceutical-grade cannabis pipeline, the agency enables a fragmented, state-by-state chaos where contaminated products slip through the cracks and patients pay the price.
Ironically, the same agency that refuses to allow MMJ to grow clean, pharmaceutical cannabis in a DEA inspected facility also looks the other way as moldy, hazardous marijuana circulates in retail dispensaries.
MMJ BioPharma: Compliant, Blocked, and Ignored
MMJ BioPharma has:
secured a DEA analytical lab registration since 2022.
Submitted applications to manufacture and grow cannabis under Schedule I for FDA clinical trials.
Secured Orphan Drug Designation from the FDA for two devastating conditions.
And yet- after seven years -no federal approval.
A Simple Question for Administrator Terry Cole
Now that the Senate has confirmed Terry Cole as DEA Administrator, the public deserves an answer:
Will you keep blocking clean, FDA-regulated cannabis research while patients unknowingly inhale moldy weed from state markets you refuse to regulate?
The answer to that question will define not only your legacy-but whether the DEA finally chooses science over sabotage.
Final Thoughts
The DEA says it exists to fight drug abuse and protect public health. But in the face of real harm- contaminated marijuana entering legal markets -it's missing in action.
It's time for a new era of leadership. One where medical science leads, and moldy lies die.
The time for excuses is over. The time for action is now.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-85832
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
A.Mahlangu--AMWN